On 9 November 2026, ValiRx (LSE:VAL) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is valirx remains in focus around its oncology and life-science intellectual …
On 9 November 2026, Thalia Therapeutics (LSE:THAT) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is thalia therapeutics remains in focus around its therapeutic development …
5 November director dealings and the September half-year report have kept attention on execution in minimally invasive surgery.
On 9 November 2026, Shield Therapeutics (LSE:STX) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is q3 2026 showed continued commercial sales growth, while the …
On 9 November 2026, Sareum (LSE:SAR) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is sareum remains in focus around its oncology drug-development programme and …
On 9 November 2026, RUA Life Sciences (LSE:RUA) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is rua life sciences remains in focus around its …
On 9 November 2026, Renalytix (LSE:RENX) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is renalytix remains on the radar as investors monitor commercialisation of …
• Thalia has transformed into a clinical-stage RNA therapeutics company following theAcquisitionof Sanmirna Therapeutics. Its Phase 1 study of THAT-001, or miRisten, in relapsed or refractory acute myeloid leukaemia is progressing, with top-line data targeted for the first half of 2027.
• RTW Venture Fund provides listed exposure to a portfolio of biotechnology and life-sciences companies, with capital allocation linked to clinical and commercial milestones. An expansion of the capital allocation plan can affect portfolio construction,Liquidityand the pace at which new opportunities are funded.
• Oxford Biodynamics develops epigenetic biomarkers using its EpiSwitch platform, with applications across oncology, diagnostics and drug development. ItsInvestmentcase is linked to scientific validation, partnerships, commercial adoption and the conversion of research programmes intoRecurring Revenueopportunities.